echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > NEJM: Comparison of the efficacy of Bimekizumab and Adalimumab on plaque psoriasis, is the king born?

    NEJM: Comparison of the efficacy of Bimekizumab and Adalimumab on plaque psoriasis, is the king born?

    • Last Update: 2021-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Bimekizumab is a unique molecule with a dual mechanism of action.
    This is a new type of humanized monoclonal IgG1 antibody that can potently and selectively neutralize IL-17A and IL-17F, which are two types of driving the inflammatory process Key cytokines
    .
    IL-17A and IL-17F have similar pro-inflammatory functions, and independently cooperate with other inflammatory mediators to drive chronic inflammation and damage in multiple tissues


    .


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.